Android app on Google Play

Needham & Company Starts Tetralogic Pharmaceuticals (TLOG) at Buy

January 6, 2014 7:24 AM EST Send to a Friend
Get Alerts TLOG Hot Sheet
Price: $5.14 +4.47%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 20 | Down: 9 | New: 24
Trade TLOG Now!
Join SI Premium – FREE
Needham & Company initiates coverage on Tetralogic Pharmaceuticals (NASDAQ: TLOG) with a Buy. PT $16.00.

Analyst Chad Messer, Ph.D. explains the new rating: "TetraLogic is developing birinapant, a targeted cancer treatment that works by inducing apoptosis, or programmed cell death. Birinapant is part of a class of molecules called IAP inhibitors that have been of great interest to the pharmaceutical industry, but difficult to target safely and effectively. TetraLogic solved this discovery problem and is now developing birinapant as a best-in-class IAP inhibitor with a well established safety profile in multiple indications for cancer and infectious disease. We find the valuation of TLOG shares compelling given the multiple ways that we see for the company to create value in the coming 1-2 years."

For an analyst ratings summary and ratings history on Tetralogic Pharmaceuticals click here. For more ratings news on Tetralogic Pharmaceuticals click here.

Shares of Tetralogic Pharmaceuticals closed at $10.48 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, New Coverage

Related Entities

Needham & Company

Add Your Comment